Two clinically relevant tumor cell lines, renal carcinoma (Caki2) and glioblastoma (U87), were selected for functional validation (Supplementary Figures S2, S3) since mTOR inhibitors are used as a treatment for these two types of tumors (Pantuck et al., 2006; Brugarolas et al., 2008; Cloughesy et al., 2008) and because our data suggested that these two cell lines were relatively more sensitive to mTOR inhibitor treatment. This evidence concerns the gene MTOR and glioblastoma.